Vatta Adriano F, Everett William R, Holzmer Susan J, Cherni Judith A, King Vickie L, Rugg Douglas, Geurden Thomas
Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007, USA.
BerTek, Inc., P.O. Box 606, Greenbrier, AR 72058, USA.
Vet Parasitol. 2017 Apr;238 Suppl 1:S22-S26. doi: 10.1016/j.vetpar.2017.02.026.
A new spot-on formulation of selamectin plus sarolaner was evaluated against fleas for adulticidal efficacy, and for the effect on egg production and hatching when applied to flea-infested cats. Ten male and ten female adult domestic shorthair cats were randomly assigned to one of two treatment groups based on pre-treatment flea counts. Cats received topical treatment on Day 0 in a single spot to the dorsal scapular area with either a placebo formulation or with the combination formulation at the minimal dose of 6.0mg selamectin plus 1.0mg sarolaner per kg bodyweight. On Days -1, 5, 12, 19, 26 and 33, cats were infested with approximately 100 (±5) unfed Ctenocephalides felis fleas. At 24h after treatment or 48h after subsequent flea infestation, cats were housed for a 20-h period in a cage to allow collection of flea eggs. At the end of this period, flea eggs were collected from the cages and cats were combed to remove and count live fleas. Emerged viable larvae and emerged adult fleas were counted 3days and 35days, respectively, after egg collection. The new spot-on formulation of selamectin plus sarolaner provided 100% efficacy against adult fleas up to Day 36 following a single application. Fleas on placebo-treated cats produced large numbers of eggs throughout the study, with individual counts ranging from 110 to 1256 eggs. Following treatment, four flea eggs were collected from a single selamectin/sarolaner-treated cat on Day 29, but there were no eggs collected from any other selamectin/sarolaner-treated animal during the study. No larvae or adult fleas developed from these four eggs. From the eggs collected from the placebo-treated cats, the mean percentage of live larvae and adults that emerged ranged from 67.3% to 84.2% and from 50.7% to 81.8%, respectively. A single topical treatment with a new spot-on formulation of selamectin plus sarolaner at the minimum label dose thus controlled fleas on cats and was 100% effective in preventing flea reproduction for over one month after treatment.
对一种新的含塞拉菌素和沙罗拉纳的滴剂配方进行了评估，以确定其对跳蚤的成虫杀灭效果，以及应用于感染跳蚤的猫时对产卵和孵化的影响。根据治疗前的跳蚤计数，将10只雄性和10只雌性成年家养短毛猫随机分配到两个治疗组之一。在第0天，猫在肩胛背部区域单次滴涂安慰剂配方或最低剂量为每千克体重6.0毫克塞拉菌素加1.0毫克沙罗拉纳的联合配方进行局部治疗。在第-1、5、12、19、26和33天，给猫感染大约100（±5）只未进食的猫栉首蚤。在治疗后24小时或随后跳蚤感染后48小时，将猫关在笼子里20小时，以便收集跳蚤卵。在此期间结束时，从笼子里收集跳蚤卵，并梳理猫以去除并计数活跳蚤。在收集卵后3天和35天分别对孵化出的存活幼虫和成年跳蚤进行计数。含塞拉菌素和沙罗拉纳的新滴剂配方单次应用后在第36天之前对成年跳蚤的杀灭效果达100%。在整个研究过程中，接受安慰剂治疗的猫身上的跳蚤产下大量卵，个体计数范围为110至1256枚卵。治疗后，在第29天从一只接受塞拉菌素/沙罗拉纳治疗的猫身上收集到4枚跳蚤卵，但在研究期间没有从任何其他接受塞拉菌素/沙罗拉纳治疗的动物身上收集到卵。这4枚卵没有孵化出幼虫或成年跳蚤。从接受安慰剂治疗的猫身上收集的卵中孵出的存活幼虫和成年跳蚤的平均百分比分别为67.3%至84.2%和50.7%至81.8%。因此，以最低标签剂量单次局部应用含塞拉菌素和沙罗拉纳的新滴剂配方可控制猫身上的跳蚤，并且在治疗后一个多月内对防止跳蚤繁殖的效果达100%。
